In 2023, the United Kingdom led the sales of Global Systemic Hormonal Preparations (Excluding Sex Hormones and Insulins), valued at $747.2 million, demonstrating a steady growth trend with a year-on-year increase of 3.02%. Croatia and Australia followed with significant sales, also showing healthy positive variations of 2.47% and 3.4%, respectively. Estonia recorded the highest year over year growth at 3.51%, albeit from a smaller base. In contrast, Denmark saw a slight decline of 0.027%. Over the past five years, the compound annual growth rate for these countries shows resilient demand and expansion patterns in the sector.
Future trends to watch include:
- Potential impact of technological advancements in drug delivery systems.
- Increasing awareness and diagnosis rates for hormonal disorders.
- Regulatory changes affecting market access and pricing across different regions.
- Emerging markets where growth opportunities may arise due to unmet medical needs.
Top countries in Systemic Hormonal Preparations Sales (Excluding Sex Hormones and Insulins) by Country
| # | 10 Countries | Million US Dollars PPP | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 United Kingdom | 747.2 | 2023 | +1.16% | +3.02% | View data |
| 2 | 2 Croatia | 303.4 | 2023 | +4.12% | +2.47% | View data |
| 3 | 3 Australia | 197.7 | 2023 | +2.49% | +3.4% | View data |
| 4 | 4 Chile | 179.9 | 2023 | +3.04% | +2.66% | View data |
| 5 | 5 Czech Republic | 165.9 | 2023 | +2.47% | +0.42% | View data |
| 6 | 6 Sweden | 129.7 | 2023 | +1.33% | +1.07% | View data |
| 7 | 7 Austria | 89.9 | 2023 | +2.98% | +3.2% | View data |
| 8 | 8 Ireland | 77 | 2023 | +0.92% | +1.44% | View data |
| 9 | 9 Denmark | 73.8 | 2023 | +1.93% | -0.027% | View data |
| 10 | 10 Finland | 61.1 | 2023 | +2.35% | +2.09% | View data |
